Home | Contact Us | Site Map
Dhtml Menu Css by Vista-Buttons.com v5.7
NanoStat™ Platform

NanoBio’s vaccine adjuvant technology employs high-energy, oil-in-water nanoemulsions (NE) that are manufactured at an average size of 400-500 nanometers. The NE adjuvant has several key attributes, including:

  • Enables IN, IM, or SQ administration
  • Adjuvants multiple antigen types, including recombinant proteins, attenuated viruses, whole pathogens and other antigens
  • Stimulates a balanced Th1/Th2 immune response
  • Elicits IL17 for mucosal protection following IN administration1
  • Has inherent antimicrobial activity in vitro, and thereby can convert live pathogens into highly effective split vaccines


When used with intranasal vaccination, the NE adjuvant elicits both mucosal and systemic immunity. The technology is therefore uniquely suited to enable vaccines for both respiratory & sexually transmitted infections, which involve pathogens that enter the body across mucosal surfaces. The mucosal immunity elicited by NE vaccines provides protection against these infections at their port of entry, and has demonstrated the potential to reduce carriage of the associated pathogen.

How Do Intranasal NE Vaccines Work?


NE vaccines can be applied intranasally using either a dropper or a sprayer device. As shown in the figure below, the vaccine droplets readily permeate the nasal tissue which is rich in immune-presenting cells. Dendritic cells sample the vaccine at the nasal mucosa, and carry the antigen back to the immune system to elicit both a mucosal and a systemic response.2 Intranasal NE vaccines have been shown to be immunogenic, safe and well tolerated in Phase 1 clinical trials.

Studies Conducted to Date

NanoBio has conducted numerous vaccine studies demonstrating the key attributes of the NE adjuvant, encompassing several diseases and animal models.  A selection of studies completed to date is summarized below:

Disease

Antigens

Models

Routes

Outcomes

Respiratory Infections

Seasonal Flu:

Fluzone®, Fluvirin®

βPL-H3N2, NE-split H3N2

Mice, rabbits, ferrets, man

IN, IM, SQ

Immunogenicity, HAI, protection against challenge

RSV:

NE-split RSV, F protein

Mice, cotton rats, NHP’s

IN, IM

Immunogenicity, neutralizing antibodies, protection against challenge

Anthrax:

rPA

Mice, guinea pigs, rabbits

IN, IM

Immunogenicity, neutralizing antibodies, protection against challenge

Pandemic Flu:

rHA (H5)

Mice

IN, IM, SQ

Immunogenicity, HAI

Sexually Transmitted Diseases

HSV-2:

gD2, NE-split HSV2

Guinea pigs

IN, IM

Immunogenicity, neutralizing antibodies, protection against challenge

HIV:

Gp120

Mice

IN, IM

Immunogenicity, neutralizing antibodies, vaginal IgG & IgA


1 Immunol. 2010; 30(2): 189-199. "Induction of Th17 Cellular Immunity With a Novel Nanoemulsion Adjuvant"


2 Eur. J. Immunol. 2012. 42: 1-14; "Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking”

BlueLine

© NanoBio® Corporation 2014
NanoBio is a registered trademark of NanoBio Corporation.
All other company, brand, and product names are or may be trademarks of their respective holders. Website by Mellon & Associates, LLC.